Cosentyx (secukinumab) is a medication used to treat various autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. The ideal level range for Cosentyx may vary depending on the specific condition being treated and the patient's response to the medication.

According to the drug patent watch [1], the recommended dosage of Cosentyx is 300 mg administered by subcutaneous injection at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. However, the dosage may be adjusted based on the patient's response to the medication.

The official Cosentyx website [2] states that the medication should be administered by a healthcare professional and the dosage should be individualized based on the patient's medical history, current health status, and response to treatment. The website also notes that blood tests may be used to monitor the patient's response to the medication and adjust the dosage accordingly.

A study published in the Journal of Clinical and Aesthetic Dermatology [3] found that patients with moderate to severe psoriasis who received Cosentyx had significant improvement in their symptoms. The study also found that the medication was generally well-tolerated, with no serious adverse events reported.

In conclusion, the ideal Cosentyx level range may vary depending on the specific condition being treated and the patient's response to the medication. The recommended dosage is 300 mg administered by subcutaneous injection at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks, but the dosage may be adjusted based on the patient's response to the medication. Blood tests may be used to monitor the patient's response to the medication and adjust the dosage accordingly.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.cosentyx.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065121/